Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
You may also be interested in...
One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.
However, recruitment for adult trials remains robust, OWS’ Slaoui says.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.